NASDAQ:NPCE NeuroPace (NPCE) Stock Price, News & Analysis $14.28 +0.13 (+0.92%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$14.27 -0.01 (-0.07%) As of 09/18/2026 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About NeuroPace Stock (NASDAQ:NPCE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get NeuroPace alerts:Sign Up Key Stats Today's Range$14.05▼$14.5650-Day Range$12.89▼$17.1252-Week Range$9.22▼$19.60Volume235,521 shsAverage Volume116,372 shsMarket Capitalization$490.09 millionP/E RatioN/ADividend YieldN/APrice Target$19.33Consensus RatingModerate Buy Company Overview NeuroPace, Inc. is a medical technology company focused on developing therapies for people with drug-resistant epilepsy. The company’s principal product is the RNS System, an implantable responsive neurostimulation device designed to monitor brain activity, identify patterns associated with seizures, and deliver targeted electrical stimulation intended to reduce seizure frequency. The RNS System includes an implanted neurostimulator, leads placed near seizure-producing areas of the brain, and external software and programming tools used by clinicians. The system also collects neurological data that can help physicians evaluate seizure patterns and tailor treatment. NeuroPace has developed related data-management and clinical-support capabilities to assist healthcare providers in monitoring patients over time. Founded in 1997 and headquartered in Mountain View, California, NeuroPace received U.S. Food and Drug Administration approval for the RNS System in 2013. The company primarily serves patients and healthcare providers in the United States through its epilepsy-focused product portfolio and clinical network.AI Generated. May Contain Errors. Read More NeuroPace Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreNPCE MarketRank™: NeuroPace scored higher than 64% of companies evaluated by MarketBeat, and ranked 282nd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingNeuroPace has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 2 strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialNeuroPace has a consensus price target of $19.33, representing about 35.4% upside from its current price of $14.28.Amount of Analyst CoverageNeuroPace has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about NeuroPace's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for NeuroPace are expected to grow in the coming year, from ($0.67) to ($0.21) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NeuroPace is -25.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NeuroPace is -25.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeuroPace has a P/B Ratio of 25.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about NeuroPace's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.29% of the float of NeuroPace has been sold short.Short Interest Ratio / Days to CoverNeuroPace has a short interest ratio ("days to cover") of 6.28.Change versus previous monthShort interest in NeuroPace has recently increased by 7.81%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeuroPace does not currently pay a dividend.Dividend GrowthNeuroPace does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.47 News SentimentNeuroPace has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for NeuroPace this week, compared to 3 articles on an average week.MarketBeat Follows1 people have added NeuroPace to their MarketBeat watchlist in the last 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, NeuroPace insiders have not sold or bought any company stock.Percentage Held by Insiders19.20% of the stock of NeuroPace is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions78.83% of the stock of NeuroPace is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about NeuroPace's insider trading history. Receive NPCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuroPace and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NPCE Stock News HeadlinesKeyBanc Initiates NeuroPace at Overweight With $18 Price TargetSeptember 18 at 8:15 AM | marketscreener.comMNeuroPace to Participate in 2026 Cantor Global Healthcare ConferenceSeptember 1, 2026 | businesswire.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required. | Stansberry Research (Ad)NeuroPace to Participate in Wells Fargo 21st Annual Healthcare ConferenceAugust 31, 2026 | businesswire.comNeuroPace, Inc. (NPCE) Q2 2026 Earnings Call TranscriptAugust 14, 2026 | seekingalpha.comWells Fargo Gives a Buy Rating to NeuroPace (NPCE)August 13, 2026 | theglobeandmail.comNeuroPace drops as bid to expand label for RNS System denied in USJuly 30, 2026 | msn.comNeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized EpilepsyJuly 29, 2026 | finance.yahoo.comSee More Headlines NPCE Stock Analysis - Frequently Asked Questions How have NPCE shares performed this year? NeuroPace's stock was trading at $15.44 at the beginning of the year. Since then, NPCE stock has decreased by 7.5% and is now trading at $14.28. How were NeuroPace's earnings last quarter? NeuroPace, Inc. (NASDAQ:NPCE) released its quarterly earnings results on Tuesday, August, 11th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.22) by $0.04. The firm had revenue of $22.83 million for the quarter, compared to analyst estimates of $22.61 million. NeuroPace had a negative net margin of 19.34% and a negative trailing twelve-month return on equity of 105.64%. Read the conference call transcript. When did NeuroPace IPO? NeuroPace (NPCE) raised $85 million in an initial public offering (IPO) on Thursday, April 22nd 2021. The company issued 5,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Wells Fargo and SVB Leerink were co-managers. Who are NeuroPace's major shareholders? NeuroPace's top institutional shareholders include First Light Asset Management LLC (8.34%), BlackRock Inc. (7.27%), Deutsche Bank AG (2.75%) and Algert Global LLC (0.54%). Insiders that own company stock include Orbimed Advisors Llc, Martha Morrell and Ltd Kck. View institutional ownership trends. How do I buy shares of NeuroPace? Shares of NPCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NeuroPace own? Based on aggregate information from My MarketBeat watchlists, some other companies that NeuroPace investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and Jabil (JBL). Company Calendar Last Earnings8/11/2026Today9/19/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 NPCE's financial health is in the Green zone, according to TradeSmith. NPCE has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:NPCE CIK1528287 Webwww.neuropace.com Phone650-237-2700FaxN/AEmployees220Year Founded1997Price Target and Rating Average Price Target for NeuroPace$19.33 High Price Target$22.00 Low Price Target$16.00 Potential Upside/Downside+35.4%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($0.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$21.47 million Net Margins-19.34% Pretax Margin-17.96% Return on Equity-105.64% Return on Assets-16.51% Debt Debt-to-Equity Ratio4.97 Current Ratio4.94 Quick Ratio3.91 Sales & Book Value Annual Sales$99.99 million Price / Sales4.90 Cash FlowN/A Price / Cash FlowN/A Book Value$0.57 per share Price / Book25.05Miscellaneous Outstanding Shares34,320,000Free Float27,734,000Market Cap$490.09 million OptionableOptionable Beta1.94 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:NPCE) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our Partners“Elon’s nightmare” could fund your retirementMarc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredYou’ve never seen anything like this beforeFor centuries, families like the Rothschilds, Morgans, and Rockefellers have quietly used one overlooked type ...Porter & Company | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredNVDA CEO says it’s a "once-in-a-generation opportunity"NVIDIA CEO Jensen Huang calls a little-known AI niche a once-in-a-generation opportunity, and it has nothing t...Monument Traders Alliance | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroPace, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroPace With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
